NEW YORK (GenomeWeb News) —Biomarker developer Pronota has raised an additional €1.5million ($1.8 million) for a total of €7.9 million in its Series B financing round, the company said yesterday.
The Ghent, Belgium-based firm plans to use the funds raised in the round to develop technologies for cardio-renal, pre-eclampsia, sepsis, and ovarian cancer diagnostics.
The latest financing came from MedSciences Capital, the venture arm of the Dutch bank Kempen & Co., and earlier investors in the Series B round included Gimy, Biotech Fund Flanders, LSP, JJDC, KBC Private Equity, VIB, MP Healthcare Venture Management, and Baekeland Fund.
Pronota said that its central platform, which mines for low-abundance protein biomarkers in blood, has been validated by its cardio-renal and other programs, and that it now plans to launch its first diagnostic product in 2012.